In the adjuvant setting, pembrolizumab resulted in a notably longer recurrence‐free survival (RFS) and distant metastasis‐free survival, and a predictable safety profile compared with placebo in patients with resected stage III melanoma regardless of PD‐L1 tumor expression [24, 25]. This evidence concerns the gene CD274 and neoplasm.